GlassScriptPhysician profile
David A Ginnebaugh
NPI 1306952767
$9,388.81
in general payments reported to CMS, 2019-2025
42 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,222 · 2020: $1,143 · 2021: $1,457 · 2022: $1,731 · 2023: $1,289 · 2024: $1,371 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,835.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,066.96 | 2019-2025 | Repatha, Evenity, Otezla |
| Pfizer INC. | $888.40 | 2019-2025 | |
| Lilly USA, LLC | $684.45 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $660.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $635.35 | 2021-2025 | |
| Grifols USA, LLC | $571.24 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $501.14 | 2019-2025 | Jardiance, Tradjenta, Ofev |
| Astrazeneca Pharmaceuticals LP | $488.47 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $365.52 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $352.86 | 2019-2022 | |
| Glaxosmithkline, LLC. | $281.31 | 2019-2025 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $278.04 | 2021-2025 | |
| Esperion Therapeutics, INC. | $211.27 | 2020-2025 | Nexletol |
| Daiichi Sankyo INC. | $208.79 | 2020-2025 | Injectafer |
| Astellas Pharma US INC | $199.15 | 2019-2024 | Veozah, Myrbetriq |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ginnebaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.